{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:41:43Z","timestamp":1792449703903,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32370805"],"award-info":[{"award-number":["32370805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970044"],"award-info":[{"award-number":["31970044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117089","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:51:47Z","timestamp":1732611107000},"page":"117089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico"],"prefix":"10.1016","volume":"282","author":[{"given":"Dongchen","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CuiCui","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117089_bib1","first-page":"26","article-title":"Differentiation therapy of myeloid leukemia: four decades of development","volume":"106","author":"Madan","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2024.117089_bib2","article-title":"Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: design, synthesis, and biological evaluations","volume":"34","author":"Chen","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117089_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216933","article-title":"FLT3-selective PROTAC: enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia","volume":"592","author":"Tan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117089_bib4","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41375-021-01462-4","article-title":"The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML","volume":"36","author":"Charlet","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.117089_bib6","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2023-187465","article-title":"Characteristics of FLT3-ITD and efficacy of Sorafenib treatment in pediatric AML: a report from AML-BFM study group","volume":"142","author":"Antoniou","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib7","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.117089_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117089_bib9","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.117089_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11912-020-01010-w","article-title":"Mixed phenotype acute leukemia: current approaches to diagnosis and treatment","volume":"23","author":"Alexander","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2024.117089_bib11","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib13","first-page":"46","article-title":"Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications","volume":"11","author":"Cheng","year":"2008","journal-title":"Idrugs"},{"key":"10.1016\/j.ejmech.2024.117089_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V108.11.158.158","article-title":"Phase 1\/2 study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML)","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.V108.11.1374.1374","article-title":"Tandutinib (MLN518), a potent FLT3 inhibitor","volume":"108","author":"Schittenhelm","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/gutjnl-2022-329134","article-title":"Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-\u03b3 signalling","volume":"72","author":"Cao","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2024.117089_bib17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejmech.2024.117089_bib18","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/acs.jcim.0c00544","article-title":"Pattern and dynamics of FLT3 duplications","volume":"60","author":"Todde","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.117089_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114348","article-title":"Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors","volume":"183","author":"Marensi","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117089_bib20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","article-title":"Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis","volume":"93","author":"Port","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2024.117089_bib21","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2024.117089_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2024.117089_bib23","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N\u2032-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib24","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V122.21.494.494","article-title":"Results of a phase 2 randomized, open-label, study of lower doses of Quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML)","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2024.117089_bib27","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-20-3114","article-title":"Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia","volume":"27","author":"Dumas","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117089_bib28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.26447","article-title":"Gilteritinib clinical activity in relapsed\/refractory mutated acute myeloid leukemia previously treated with inhibitors","volume":"97","author":"Numan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2024.117089_bib29","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117089_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082312","article-title":"Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions","author":"Fedorov","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.117089_bib31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.117089_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.V124.21.389.389","article-title":"Results of a phase II study of Crenolanib in relapsed\/refractory acute myeloid leukemia patients (pts) with activating FLT3 mutations","volume":"124","author":"Randhawa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117089_bib34","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Allison","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2024.117089_bib35","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/cr950202r","article-title":"Quantum-chemical descriptors in QSAR\/QSPR studies","volume":"96","author":"Karelson","year":"1996","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.117089_bib36","doi-asserted-by":"crossref","first-page":"10509","DOI":"10.1021\/ja9718937","article-title":"Construction of 3D-QSAR models using the 4D-QSAR analysis formalism","volume":"119","author":"Hopfinger","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.117089_bib37","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/ci900014f","article-title":"LQTA-QSAR: a new 4D-QSAR methodology","volume":"49","author":"Martins","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.117089_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/1062936X.2023.2214870","article-title":"Synthesis, antiproliferative and 4D-QSAR studies of thiadiazole derivatives bearing acrylamide moiety as EGFR inhibitors","volume":"34","author":"Cai","year":"2023","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2024.117089_bib39","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11030-021-10181-y","article-title":"Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors","volume":"26","author":"Hu","year":"2022","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2024.117089_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108131","article-title":"4D-QSAR, ADMET properties, and molecular dynamics simulations for designing N-substituted urea\/thioureas as human glutaminyl cyclase inhibitors","volume":"112","author":"Wei","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/0115734064258994231106052633","article-title":"4D-QSAR and MIA-QSAR studies of aminobenzimidazole derivatives as fourth-generation EGFR inhibitors","volume":"20","author":"Jia","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4155\/fmc-2023-0246","article-title":"Leishmanicidal activity and 4D quantitative structure\u2013activity relationship and molecular docking studies of vanillin-containing 1,2,3-triazole derivatives","volume":"16","author":"Rodrigues Gazolla","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jmgm.2019.08.009","article-title":"4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors","volume":"92","author":"Ma","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2024.117089_bib44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s13738-019-01835-8","article-title":"Molecular docking and 4D-QSAR model of methanone derivatives by electron conformational-genetic algorithm method","volume":"17","author":"T\u00fcz\u00fcn","year":"2020","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.117089_bib45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00044-019-02303-x","article-title":"4D-QSAR studies of CB2 cannabinoid receptor inverse agonists: a comparison to 3D-QSAR","volume":"28","author":"Zhang","year":"2019","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.117089_bib46","first-page":"1548","article-title":"4D-QSAR study of 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitors","volume":"30","author":"Martins","year":"2019","journal-title":"JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY"},{"key":"10.1016\/j.ejmech.2024.117089_bib47","series-title":"ARYLAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND","author":"Shimada","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117089_bib48","series-title":"Diamino Heterocyclic Carboxamide Compound","author":"Itsuro","year":"2010"},{"key":"10.1016\/j.ejmech.2024.117089_bib49","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1021\/acs.jmedchem.3c00736","article-title":"Small-molecule hydrophobic tagging: a promising strategy of druglike Technology for targeted protein degradation","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115741","article-title":"Hydrophobic tag-based protein degradation: development, opportunity and challenge","volume":"260","author":"He","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib51","article-title":"Discovery of norbornene as a novel hydrophobic tag applied in protein degradation","volume":"62","author":"Xie","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2024.117089_bib52","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/cr100264t","article-title":"The lipophilic bullet hits the targets: medicinal Chemistry of adamantane derivatives","volume":"113","author":"Wanka","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.117089_bib53","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1021\/jp511756v","article-title":"The thermochemistry of cubane 50 Years after its synthesis: a high-level theoretical study of cubane and its derivatives","volume":"119","author":"Agapito","year":"2015","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/bc400409n","article-title":"Magnetic norbornene polymer as multiresponsive nanocarrier for site specific cancer therapy","volume":"25","author":"Rao N","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib55","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1055\/s-0037-1610143","article-title":"Norbornene in organic synthesis","volume":"50","author":"Li","year":"2018","journal-title":"SYNTHESIS-STUTTGART"},{"key":"10.1016\/j.ejmech.2024.117089_bib56","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1002\/pola.23499","article-title":"Fluorene-based materials and their supramolecular properties","volume":"47","author":"Abbel","year":"2009","journal-title":"J. Polym. Sci. Polym. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib57","doi-asserted-by":"crossref","first-page":"12324","DOI":"10.1073\/pnas.1921531117","article-title":"Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma","volume":"117","author":"Rajesh","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117089_bib58","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.ejmech.2024.117089_bib59","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1039\/D4OB01043D","article-title":"Tetraasteranes as homologues of cubanes: effective scaffolds for drug discovery","volume":"22","author":"Zhang","year":"2024","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/cn500054n","article-title":"The first CNS-active carborane: a novel P2X7 receptor antagonist with antidepressant activity","volume":"5","author":"Wilkinson","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2024.117089_bib61","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1080\/00397919708004160","article-title":"Synthesis of (trifluoromethylthio) cubanes","volume":"27","author":"Munavalli","year":"1997","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2024.117089_bib62","series-title":"Gaussian 09, Revision B.01","author":"Frisch","year":"2010"},{"issue":"9","key":"10.1016\/j.ejmech.2024.117089_bib63","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","article-title":"Acpype - AnteChamber PYthon parser interfacE","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ejmech.2024.117089_bib65","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1063\/1.465158","article-title":"Structure in liquid water: a study of spatial distribution functions","volume":"99","author":"Svishchev","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2024.117089_bib66","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2024.117089_bib67","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1103\/PhysRevLett.45.1196","article-title":"Crystal structure and pair potentials: a molecular-dynamics study","volume":"45","author":"Parrinello","year":"1980","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.ejmech.2024.117089_bib68","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ejmech.2007.06.009","article-title":"Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking","volume":"43","author":"Ravindra","year":"2008","journal-title":"Eur. J. Med. Chem."},{"issue":"58","key":"10.1016\/j.ejmech.2024.117089_bib69","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.117089_bib70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic acids research"},{"key":"10.1016\/j.ejmech.2024.117089_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2024.117089_bib72","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","article-title":"ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution","volume":"16","author":"Tian","year":"2020","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2024.117089_bib73","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2024.117089_bib74","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1021\/jp8001614","article-title":"Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations","volume":"112","author":"Joung","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2024.117089_bib75","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.ejmech.2024.117089_bib76","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/jcc.25382","article-title":"Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data","volume":"39","author":"Roe","year":"2018","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.117089_bib77","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2024.117089_bib78","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:18:38Z","timestamp":1733516318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424009711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":78,"alternative-id":["S0223523424009711"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117089","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117089"}}